In addition to anti-thyroid effects seen with treatment of the specific RAF inhibitor PLX4032 in BRAF-mutated cancer cells, we observed paradoxical activation of the MAPK pathway in BRAF-wild-type Nthy-ori 3–1 thyroid cells, as previously seen in BRAF-wild-type melanoma cells [35]. Here, BRAF is linked to cancer.